Hedgehog Pathway Inhibitors for Advanced Basal Cell Carcinoma: Optimizing Use in Clinical Practice
The 2026 ODAC Conference featured an expert panel discussion on evolving strategies for the use of hedgehog pathway inhibitors (HHIs), with a focus on practical clinical decision-making for dermatologists. Dr. Vishal Patel and Dr. C. William Hanke reviewed how HHIs have expanded treatment options for patients with locally advanced and metastatic basal cell carcinoma (BCC).
Background and Rational …
The 2026 ODAC Conference featured an expert panel discussion on evolving strategies for the use of hedgehog pathway inhibitors (HHIs), with a focus on practical clinical decision-making for dermatologists. Dr. Vishal Patel and Dr. C. William Hanke reviewed how HHIs have expanded treatment options for patients with locally advanced and metastatic basal cell carcinoma (BCC).
Background and Rational … 
Which histologic subtype of the lesion shown is most aggressive?
A. Solid
B. Nodular
C. Superficial
D. Morpheaform
E. All are equal
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
*Brand partners had no involvement in the content of the questions or answers.
… 
In the age of immunotherapy, is there a place for hedgehog inhibitors in cutaneous oncology?
ODAC Guest Advisor Dr. Vishal Patel says hedgehog inhibitors are even more important now. Dr. Patel spoke with Next Steps in Derm, in partnership with the ODAC Dermatology Conference, where he outlined scenarios in clinical treatment where hedgehog inhibitors make sense. Learn about the two approved m …